The stromal overexpression of decay accelerating factor (DAF/CD55) correlates with poor clinical outcome in colorectal cancer patients

Tae Hwa Baek, Joo Heon Kim, Mee Ja Park, Hye Kyung Lee, Hyun Jin Son, Hyun Ki Soon, Chang Nam Kim, Che Myong Ko, Dong Wook Kang

Research output: Contribution to journalArticle

Abstract

Background: Decay accelerating factor (DAF/CD55), regulates the complement system by accelerating decay of the C3 convertase, has been described in several malignancies, however, the clinicopathologic significance of CD55 and its receptor CD97 has not been fully investigated. We examined the expression patterns of both CD55 and CD97 and their association with clinicopathologic parameters in colorectal cancers (CRCs). Methods: Expression patterns of CD55 and CD97 in the stroma and tumor cells at tumor center and invasive front were examined in 130 CRCs, and their significance was statistically evaluated. Results: CD55-high stroma was correlated with tumor border (p=0.006) and invasion depth (p=0.013). CD55-high tumor cells at tumor center and invasive front were correlated with histologic grade, and CD55-high tumor cells at invasive front with tumor, node and metastasis (TNM) stage (p<0.05). CD97-high stroma was correlated with lymph node metastasis (p=0.016) and TNM stage (p=0.030). CD97-high tumor cells at tumor center and invasive front were correlated with tumor size and CD97-high tumor cells at tumor center with tumor border (p<0.05). Patients with CD55-high stroma showed poor overall and recurrence-free survival (p<0.05) in univariate analysis, and were independently associated with short recurrence-free survival (p=0.025) in multivariate analysis. Conclusions: Stromal CD55 overexpression would be an indicator of adverse clinical outcome and a useful prognostic factor.

Original languageEnglish (US)
Pages (from-to)445-454
Number of pages10
JournalKorean Journal of Pathology
Volume45
Issue number5
DOIs
StatePublished - Oct 2011

Fingerprint

CD55 Antigens
Colorectal Neoplasms
Neoplasms
Neoplasm Metastasis
Complement C3-C5 Convertases
Recurrence
Survival

Keywords

  • CD97
  • Colorectal cancers
  • Decay accelerating factor (DAF/CD55)
  • Immunohistochemistry
  • Prognostic factor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The stromal overexpression of decay accelerating factor (DAF/CD55) correlates with poor clinical outcome in colorectal cancer patients. / Baek, Tae Hwa; Kim, Joo Heon; Park, Mee Ja; Lee, Hye Kyung; Son, Hyun Jin; Soon, Hyun Ki; Kim, Chang Nam; Ko, Che Myong; Kang, Dong Wook.

In: Korean Journal of Pathology, Vol. 45, No. 5, 10.2011, p. 445-454.

Research output: Contribution to journalArticle

Baek, Tae Hwa ; Kim, Joo Heon ; Park, Mee Ja ; Lee, Hye Kyung ; Son, Hyun Jin ; Soon, Hyun Ki ; Kim, Chang Nam ; Ko, Che Myong ; Kang, Dong Wook. / The stromal overexpression of decay accelerating factor (DAF/CD55) correlates with poor clinical outcome in colorectal cancer patients. In: Korean Journal of Pathology. 2011 ; Vol. 45, No. 5. pp. 445-454.
@article{358b0a3ecfb840e4a5d4a86ea5d6a3b5,
title = "The stromal overexpression of decay accelerating factor (DAF/CD55) correlates with poor clinical outcome in colorectal cancer patients",
abstract = "Background: Decay accelerating factor (DAF/CD55), regulates the complement system by accelerating decay of the C3 convertase, has been described in several malignancies, however, the clinicopathologic significance of CD55 and its receptor CD97 has not been fully investigated. We examined the expression patterns of both CD55 and CD97 and their association with clinicopathologic parameters in colorectal cancers (CRCs). Methods: Expression patterns of CD55 and CD97 in the stroma and tumor cells at tumor center and invasive front were examined in 130 CRCs, and their significance was statistically evaluated. Results: CD55-high stroma was correlated with tumor border (p=0.006) and invasion depth (p=0.013). CD55-high tumor cells at tumor center and invasive front were correlated with histologic grade, and CD55-high tumor cells at invasive front with tumor, node and metastasis (TNM) stage (p<0.05). CD97-high stroma was correlated with lymph node metastasis (p=0.016) and TNM stage (p=0.030). CD97-high tumor cells at tumor center and invasive front were correlated with tumor size and CD97-high tumor cells at tumor center with tumor border (p<0.05). Patients with CD55-high stroma showed poor overall and recurrence-free survival (p<0.05) in univariate analysis, and were independently associated with short recurrence-free survival (p=0.025) in multivariate analysis. Conclusions: Stromal CD55 overexpression would be an indicator of adverse clinical outcome and a useful prognostic factor.",
keywords = "CD97, Colorectal cancers, Decay accelerating factor (DAF/CD55), Immunohistochemistry, Prognostic factor",
author = "Baek, {Tae Hwa} and Kim, {Joo Heon} and Park, {Mee Ja} and Lee, {Hye Kyung} and Son, {Hyun Jin} and Soon, {Hyun Ki} and Kim, {Chang Nam} and Ko, {Che Myong} and Kang, {Dong Wook}",
year = "2011",
month = "10",
doi = "10.4132/KoreanJPathol.2011.45.5.445",
language = "English (US)",
volume = "45",
pages = "445--454",
journal = "Journal of Pathology and Translational Medicine",
issn = "2383-7837",
publisher = "Korean Society of Pathologists",
number = "5",

}

TY - JOUR

T1 - The stromal overexpression of decay accelerating factor (DAF/CD55) correlates with poor clinical outcome in colorectal cancer patients

AU - Baek, Tae Hwa

AU - Kim, Joo Heon

AU - Park, Mee Ja

AU - Lee, Hye Kyung

AU - Son, Hyun Jin

AU - Soon, Hyun Ki

AU - Kim, Chang Nam

AU - Ko, Che Myong

AU - Kang, Dong Wook

PY - 2011/10

Y1 - 2011/10

N2 - Background: Decay accelerating factor (DAF/CD55), regulates the complement system by accelerating decay of the C3 convertase, has been described in several malignancies, however, the clinicopathologic significance of CD55 and its receptor CD97 has not been fully investigated. We examined the expression patterns of both CD55 and CD97 and their association with clinicopathologic parameters in colorectal cancers (CRCs). Methods: Expression patterns of CD55 and CD97 in the stroma and tumor cells at tumor center and invasive front were examined in 130 CRCs, and their significance was statistically evaluated. Results: CD55-high stroma was correlated with tumor border (p=0.006) and invasion depth (p=0.013). CD55-high tumor cells at tumor center and invasive front were correlated with histologic grade, and CD55-high tumor cells at invasive front with tumor, node and metastasis (TNM) stage (p<0.05). CD97-high stroma was correlated with lymph node metastasis (p=0.016) and TNM stage (p=0.030). CD97-high tumor cells at tumor center and invasive front were correlated with tumor size and CD97-high tumor cells at tumor center with tumor border (p<0.05). Patients with CD55-high stroma showed poor overall and recurrence-free survival (p<0.05) in univariate analysis, and were independently associated with short recurrence-free survival (p=0.025) in multivariate analysis. Conclusions: Stromal CD55 overexpression would be an indicator of adverse clinical outcome and a useful prognostic factor.

AB - Background: Decay accelerating factor (DAF/CD55), regulates the complement system by accelerating decay of the C3 convertase, has been described in several malignancies, however, the clinicopathologic significance of CD55 and its receptor CD97 has not been fully investigated. We examined the expression patterns of both CD55 and CD97 and their association with clinicopathologic parameters in colorectal cancers (CRCs). Methods: Expression patterns of CD55 and CD97 in the stroma and tumor cells at tumor center and invasive front were examined in 130 CRCs, and their significance was statistically evaluated. Results: CD55-high stroma was correlated with tumor border (p=0.006) and invasion depth (p=0.013). CD55-high tumor cells at tumor center and invasive front were correlated with histologic grade, and CD55-high tumor cells at invasive front with tumor, node and metastasis (TNM) stage (p<0.05). CD97-high stroma was correlated with lymph node metastasis (p=0.016) and TNM stage (p=0.030). CD97-high tumor cells at tumor center and invasive front were correlated with tumor size and CD97-high tumor cells at tumor center with tumor border (p<0.05). Patients with CD55-high stroma showed poor overall and recurrence-free survival (p<0.05) in univariate analysis, and were independently associated with short recurrence-free survival (p=0.025) in multivariate analysis. Conclusions: Stromal CD55 overexpression would be an indicator of adverse clinical outcome and a useful prognostic factor.

KW - CD97

KW - Colorectal cancers

KW - Decay accelerating factor (DAF/CD55)

KW - Immunohistochemistry

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=84863047979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863047979&partnerID=8YFLogxK

U2 - 10.4132/KoreanJPathol.2011.45.5.445

DO - 10.4132/KoreanJPathol.2011.45.5.445

M3 - Article

AN - SCOPUS:84863047979

VL - 45

SP - 445

EP - 454

JO - Journal of Pathology and Translational Medicine

JF - Journal of Pathology and Translational Medicine

SN - 2383-7837

IS - 5

ER -